BACKGROUND: Active infective endocarditis (IE) is a serious disease associated with high mortality. The current study represents our experience over 18 years with surgical treatment for active infective native and prosthetic valve endocarditis (INVE, IPVE). METHOD: Analysis of 413 patients (171 with IPVE vs. 242 with INVE) who underwent cardiac surgery due to IE between 2002 and 2020. RESULTS: Patients with IPVE were significantly older (64.9 ± 13.2 years vs. 58.3 ± 15.5 years; p < 0.001) with higher EuroSCORE II (21.2 (12.7; 41.8) vs. 6.9 (3.0; 17.0); p < 0.001)) and coronary heart disease (50.6% vs. 38.0%; p < 0.011). Preoperative embolization was significantly higher within INVE (35.5% vs. 16.4%; p < 0.001) with high incidence of cerebral embolization (18.6% vs. 7.6%; p = 0.001) and underwent emergency curative surgery than the IPVE group (19.6% vs. 10.6%; p < 0.001). However, patients with IPVE were significantly represented with intracardiac abscess (44.4% vs.15.7%; p < 0.001). Intraoperatively, the duration of surgery was expectedly significantly higher in the IPVE group (356 min vs. 244 min.; p = 0.001) as well as transfusion of blood (4 units (0-27) vs. 2 units (0-14); p < 0.001). Post-operatively, the incidence of bleeding was markedly higher within the IPVE group (700 mL (438; 1163) vs. 500 mL (250; 1075); p = 0.005). IPVE required significantly more permanent pacemakers (17.6% vs. 7.5%: p = 0.002). The 30-day mortality was higher in the IPVE group (24.6% vs. 13.2%; p < 0.003). CONCLUSION: Patients with INVE suffered from a higher incidence of cerebral embolization and neurological deficits than patients with IPVE. Surgical treatment in INVE is performed mostly as an emergency indication. However, patients with IPVE were represented commonly with intracardiac abscess, and had a higher indication of pacemaker implantation. The short- and long-term mortality rate among those patients was still high.
BACKGROUND: Active infective endocarditis (IE) is a serious disease associated with high mortality. The current study represents our experience over 18 years with surgical treatment for active infective native and prosthetic valve endocarditis (INVE, IPVE). METHOD: Analysis of 413 patients (171 with IPVE vs. 242 with INVE) who underwent cardiac surgery due to IE between 2002 and 2020. RESULTS:Patients with IPVE were significantly older (64.9 ± 13.2 years vs. 58.3 ± 15.5 years; p < 0.001) with higher EuroSCORE II (21.2 (12.7; 41.8) vs. 6.9 (3.0; 17.0); p < 0.001)) and coronary heart disease (50.6% vs. 38.0%; p < 0.011). Preoperative embolization was significantly higher within INVE (35.5% vs. 16.4%; p < 0.001) with high incidence of cerebral embolization (18.6% vs. 7.6%; p = 0.001) and underwent emergency curative surgery than the IPVE group (19.6% vs. 10.6%; p < 0.001). However, patients with IPVE were significantly represented with intracardiac abscess (44.4% vs.15.7%; p < 0.001). Intraoperatively, the duration of surgery was expectedly significantly higher in the IPVE group (356 min vs. 244 min.; p = 0.001) as well as transfusion of blood (4 units (0-27) vs. 2 units (0-14); p < 0.001). Post-operatively, the incidence of bleeding was markedly higher within the IPVE group (700 mL (438; 1163) vs. 500 mL (250; 1075); p = 0.005). IPVE required significantly more permanent pacemakers (17.6% vs. 7.5%: p = 0.002). The 30-day mortality was higher in the IPVE group (24.6% vs. 13.2%; p < 0.003). CONCLUSION:Patients with INVE suffered from a higher incidence of cerebral embolization and neurological deficits than patients with IPVE. Surgical treatment in INVE is performed mostly as an emergency indication. However, patients with IPVE were represented commonly with intracardiac abscess, and had a higher indication of pacemaker implantation. The short- and long-term mortality rate among those patients was still high.
Entities:
Keywords:
infective native valve endocarditis; infective prosthetic valve endocarditis; intensive care therapy for infective endocarditis
Authors: Elfriede Ruttmann; Johann Willeit; Hanno Ulmer; Orest Chevtchik; Daniel Höfer; Werner Poewe; Günther Laufer; Ludwig C Müller Journal: Stroke Date: 2006-06-22 Impact factor: 7.914
Authors: Philip Y K Pang; Yoong Kong Sin; Chong Hee Lim; Teing Ee Tan; See Lim Lim; Victor T T Chao; Yeow Leng Chua Journal: Eur J Cardiothorac Surg Date: 2014-07-15 Impact factor: 4.191
Authors: Nicola Luciani; Eugenio Mossuto; Davide Ricci; Marco Luciani; Marco Russo; Antonio Salsano; Alberto Pozzoli; Michele D Pierri; Augusto D'Onofrio; Giovanni A Chiariello; Franco Glieca; Alberto Canziani; Mauro Rinaldi; Paolo Nardi; Valentina Milazzo; Enrico M Trecarichi; Francesco Santini; Michele De Bonis; Lucia Torracca; Eleonora Bizzotto; Mario Tumbarello Journal: Eur J Cardiothorac Surg Date: 2017-10-01 Impact factor: 4.191
Authors: Mahesh B Manne; Nabin K Shrestha; Bruce W Lytle; Edward R Nowicki; Eugene Blackstone; Steven M Gordon; Gosta Pettersson; Thomas G Fraser Journal: Ann Thorac Surg Date: 2011-12-28 Impact factor: 4.330
Authors: Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Stuart A Dickerman; Elias Abrutyn; Bruno Barsic; Emilio Bouza; Enrico Cecchi; Asuncion Moreno; Thanh Doco-Lecompte; Damon P Eisen; Claudio Q Fortes; Vance G Fowler; Stamatios Lerakis; Jose M Miro; Paul Pappas; Gail E Peterson; Ethan Rubinstein; Daniel J Sexton; Fredy Suter; Pilar Tornos; Dominique W Verhagen; Christopher H Cabell Journal: Am Heart J Date: 2007-09-12 Impact factor: 4.749
Authors: Andrew Wang; Eugene Athan; Paul A Pappas; Vance G Fowler; Lars Olaison; Carlos Paré; Benito Almirante; Patricia Muñoz; Marco Rizzi; Christoph Naber; Mateja Logar; Pierre Tattevin; Diana L Iarussi; Christine Selton-Suty; Sandra Braun Jones; José Casabé; Arthur Morris; G Ralph Corey; Christopher H Cabell Journal: JAMA Date: 2007-03-28 Impact factor: 56.272
Authors: W G Daniel; A Mügge; R P Martin; O Lindert; D Hausmann; B Nonnast-Daniel; J Laas; P R Lichtlen Journal: N Engl J Med Date: 1991-03-21 Impact factor: 91.245